<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03301779</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-0001</org_study_id>
    <nct_id>NCT03301779</nct_id>
  </id_info>
  <brief_title>Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial</brief_title>
  <official_title>Clinical Investigation to Evaluate the New Health Sciences Hemanext® Oxygen Reduction System for Leukoreduced Red Blood Cells With CP2D Anticoagulant and AS-3 Additive - Pivotal Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemanext</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hemanext</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of Hemanext. is to improve red cell storage through novel storage methods.&#xD;
      Based on our review of the pertinent literature, there is substantial evidence suggesting&#xD;
      that prolonged exposure to oxygen during storage results in oxidative damage to the red blood&#xD;
      cells leading to decreased therapeutic potential. Therefore, removal of oxygen from red blood&#xD;
      cell products prior to storage has potential to preserve the cells in a more physiologically&#xD;
      relevant state.&#xD;
&#xD;
      Currently, Hemanext has focused on the design and development of a dual compartment bag&#xD;
      system designated as the Hemanext Red Blood Cell Processing System. After standard processing&#xD;
      of donated whole blood units into leukoreduced packed red blood cells (LR-RBCs) with the&#xD;
      appropriate additive solutions, the LR-RBCs would then be placed in the oxygen reduction bag&#xD;
      (ORB) which allows for the rapid diffusion of oxygen out of the blood, through a sterile,&#xD;
      oxygen-permeable membrane, and into iron-based oxygen sorbents. After processing, the blood&#xD;
      is transferred again from the ORB into the Hemanext storage bag (HSB) which will preserve the&#xD;
      anaerobic state of the LR-RBC product for the duration of cold storage.&#xD;
&#xD;
      Hemanext has conducted preliminary storage tests to ascertain the effects of anaerobic&#xD;
      storage on overall blood health in various storage solutions. The research team has focused&#xD;
      primarily on percent hemolysis, which is mandated by the FDA to remain below 1% for the&#xD;
      duration of storage, as well as ATP and 2,3-DPG levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In vitro and in vivo performance of O2/CO2 reduced red blood cells produced with the Hemanext&#xD;
      System will be used to demonstrate the acceptability the final product for clearance. To&#xD;
      accomplish this, the study will require a total of 100 studyevaluable donors. completing the&#xD;
      study. The study entails a randomized, paired, 2-x-2 crossover design where every study donor&#xD;
      (n = 10093) evaluable study donors who completes the study will donate a total of two whole&#xD;
      blood units with individual units being donated at least 56 days (8 weeks) apart. One unit&#xD;
      will be used as the test and the other unit will be used for the control. The order in which&#xD;
      the IP and the CP will be used to collect, filter and store the whole blood and appropriate&#xD;
      blood products (within the context of the crossover design) will be randomized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Actual">March 6, 2019</completion_date>
  <primary_completion_date type="Actual">March 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of Red Blood Cells With Hemolysis</measure>
    <time_frame>On day 42 of storage</time_frame>
    <description>Percentage of packed Red Blood Cell units with hemolysis at day 42 of storage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dual Label 24 Hour In Vivo % Recovery of Red Blood Cells</measure>
    <time_frame>Day 42 of storage</time_frame>
    <description>The mean 24-hour, post-transfusion, in vivo red blood cell recovery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% Red Blood Cells Recovered Post-Filtration</measure>
    <time_frame>Post-Filtration on Day 0</time_frame>
    <description>Percentage of red blood cells recovered after the filtration process.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Whole Blood Donation and Leukoreduction</condition>
  <arm_group>
    <arm_group_label>Investigational Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Product</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemanext Red Blood Cell Processing System</intervention_name>
    <description>Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.</description>
    <arm_group_label>Investigational Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study donor must be ≥ 18 years of age.&#xD;
&#xD;
          -  Study donor must be ≥ 110 pounds.&#xD;
&#xD;
          -  Study donor's body temperature must be ≤ 37.5°C / 99.5°F (oral).&#xD;
&#xD;
          -  Study donor's hemoglobin must be ≥12.5 g/dL if female and ≥13.0 g/dL if male.&#xD;
&#xD;
          -  Study donor's hematocrit must be ≥ 38% if female and ≥39% if male.Study participants&#xD;
             must meet EITHER hemoglobin or hematocrit criteria.&#xD;
&#xD;
          -  Study donor must meet all criteria per respective site's Research Blood Donation&#xD;
             Record (BDR).&#xD;
&#xD;
          -  Study donor's most recent single RBC unit donation must have been ≥56 days prior to&#xD;
             study donation.&#xD;
&#xD;
          -  Study donor's most recent double RBC unit donation must have been ≥ 112 days prior to&#xD;
             study donation.&#xD;
&#xD;
          -  Study donor must have consented to study participation by reviewing and having&#xD;
             expressed understanding the site-respective IRB-approved informed consent form prior&#xD;
             to undergoing any study related procedures.&#xD;
&#xD;
             21 CFR 50&#xD;
&#xD;
          -  Study donor's testing results from collected blood does not indicate a risk of&#xD;
             transfusion-transmitted disease (TTD)*.&#xD;
&#xD;
          -  Study donors must agree to report adverse events from the time of signing the informed&#xD;
             consent to twenty-four hours following the end of their active study involvement.&#xD;
&#xD;
          -  Female study donors must not be pregnant, expected to be pregnant or breastfeeding.&#xD;
&#xD;
          -  Female donors who participate in the in vivo portion of the study:&#xD;
&#xD;
        Women of child-bearing age must not be pregnant as determined by a negative pregnancy test&#xD;
        prior to each re-infusion. If acceptable by local procedures, post-menopausal or surgically&#xD;
        sterile women may be exempt from the pregnancy testing requirement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Study donor is &lt; 18 years of age.&#xD;
&#xD;
          -  Study donor &lt; 110 pounds.&#xD;
&#xD;
          -  Study donor's body temperature is &gt; 37.5°C / 99.5°F (oral).&#xD;
&#xD;
          -  Study donor's hemoglobin is &lt; 12.5 g/dL if female and &lt; 13.0 g/dL if male.&#xD;
&#xD;
          -  Study donor's hematocrit is &lt; 38% if female and &lt; 39% if male.&#xD;
&#xD;
          -  Study donor does not meet all criteria per respective site's Research Blood Donation&#xD;
             Record (BDR).&#xD;
&#xD;
          -  Study donor's most recent single RBC unit donation was &lt; 56 days prior to study&#xD;
             donation.&#xD;
&#xD;
          -  Study donor's most recent double RBC unit donation was &lt; 112 days prior to study&#xD;
             donation.&#xD;
&#xD;
          -  Study donor has not consented to study participation.&#xD;
&#xD;
          -  Study donor's testing results from collected blood does indicate a risk of&#xD;
             transfusion-transmitted disease (TTD)*.&#xD;
&#xD;
          -  Female donors who participate in the in vivo portion of the study: study donor is&#xD;
             pregnant, expected to be pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faye West, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Red Cross Mid-Atlantic Research Facility</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose A Cancelas Perez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoxworth Blood Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Karafin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Versiti</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoxworth Blood Center, University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Red Cross Mid-Atlantic Research Facility</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <results_first_submitted>August 13, 2019</results_first_submitted>
  <results_first_submitted_qc>March 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 17, 2020</results_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Red Blood Cells</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03301779/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were immediately assigned to a group upon enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Investigational Product First, Then Control Product</title>
          <description>A donor randomized to this arm donated their first whole blood unit to be stored with the Investigational Product.These units were processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.&#xD;
These donors then donated their second whole blood unit to be stored with the Control Product. These units were stored in a Haemonetics Leukotrap Whole Blood System for 42 days at 1-6°C.</description>
        </group>
        <group group_id="P2">
          <title>Control Product First, Then Investigational Product</title>
          <description>A donor randomized to this arm donated their first whole blood unit to be stored with the Control Product. These units were stored in a Haemonetics Leukotrap Whole Blood System for 42 days at 1-6°C.&#xD;
These donors then donated their second whole blood unit to be stored with the Investigational Product.These units were processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Donors</title>
          <description>This study was a crossover design and all Donors donated units to both the Investigation and Control arms so the Baseline Measures for all donors are combined here irrespective of their randomization.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>% of Red Blood Cells With Hemolysis</title>
        <description>Percentage of packed Red Blood Cell units with hemolysis at day 42 of storage.</description>
        <time_frame>On day 42 of storage</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigational Product</title>
            <description>Blood products from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System.&#xD;
Hemanext Red Blood Cell Processing System: Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.</description>
          </group>
          <group group_id="O2">
            <title>Control Product</title>
            <description>Blood products from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.</description>
          </group>
        </group_list>
        <measure>
          <title>% of Red Blood Cells With Hemolysis</title>
          <description>Percentage of packed Red Blood Cell units with hemolysis at day 42 of storage.</description>
          <units>% of Red Blood Cells with Hemolysis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.168"/>
                    <measurement group_id="O2" value="0.29" spread="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dual Label 24 Hour In Vivo % Recovery of Red Blood Cells</title>
        <description>The mean 24-hour, post-transfusion, in vivo red blood cell recovery.</description>
        <time_frame>Day 42 of storage</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigational Product</title>
            <description>Blood products from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System.&#xD;
Hemanext Red Blood Cell Processing System: Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.</description>
          </group>
          <group group_id="O2">
            <title>Control Product</title>
            <description>Blood products from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.</description>
          </group>
        </group_list>
        <measure>
          <title>Dual Label 24 Hour In Vivo % Recovery of Red Blood Cells</title>
          <description>The mean 24-hour, post-transfusion, in vivo red blood cell recovery.</description>
          <units>% Recovery of Red Blood Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="5.81"/>
                    <measurement group_id="O2" value="85.8" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>% Red Blood Cells Recovered Post-Filtration</title>
        <description>Percentage of red blood cells recovered after the filtration process.</description>
        <time_frame>Post-Filtration on Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigational Product</title>
            <description>Blood products from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System.&#xD;
Hemanext Red Blood Cell Processing System: Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.</description>
          </group>
          <group group_id="O2">
            <title>Control Product</title>
            <description>Blood products from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.</description>
          </group>
        </group_list>
        <measure>
          <title>% Red Blood Cells Recovered Post-Filtration</title>
          <description>Percentage of red blood cells recovered after the filtration process.</description>
          <units>% of Red Blood Cells Recovered</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" spread="1.9"/>
                    <measurement group_id="O2" value="91.1" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study-related adverse events are defined as those study participant-reported adverse events occurring within 24-hours of donation and/or transfusion. Non-study-related adverse events outside of these periods were not recorded unless they were of a nature to impact study participant evaluability, safety or data validity.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Investigational Product</title>
          <description>Blood products from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System.&#xD;
Hemanext Red Blood Cell Processing System: Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.</description>
        </group>
        <group group_id="E2">
          <title>Control Product</title>
          <description>Blood products from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicits</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Ablation</sub_title>
                <description>Participant had the procedure during their participation in the study so it was recorded as an adverse event.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Side Pain</sub_title>
                <description>This adverse event caused the participant to go see their primary care physician and lead to the discovery that they had appendicitis (recorded in the serious adverse event section)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subject called to say he had dizziness at work after donation.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Dizzyness after donation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Light-headedness after donation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Bruising or pain on arm at blood donation site</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Nausea after donation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Disclaimer: The 51-Cr/99-Tc(m) labeling for 14 study subjects occurred without prior RDRC approval and was done at a site that did not meet GMP standards.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William Iselin</name_or_title>
      <organization>Hemanext</organization>
      <phone>7813017446</phone>
      <email>william.iselin@hemanext.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

